Roberto Acosta-Dighero

Roberto Acosta-Dighero

Auto-generated profile, based on publicly available information

Roberto Acosta-Dighero

School of Physiotherapy, Faculty of Health Sciences, Universidad San Sebastian, Santiago, Chile

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
HPHomero Puppo
Homero Puppo
Rodrigo Torres-CastroRodrigo Torres-Castro
Rodrigo Torres-Castro
LCLuis Eduardo Vasconcello - Castillo
Luis Eduardo Vasconcello - Castillo
RARoberto Acosta‐Dighero
Roberto Acosta‐Dighero
NSNicolás Sepúlveda‐Cáceres
Nicolás Sepúlveda‐Cáceres
JVJordi Vilaró
Jordi Vilaró

12 July 2020 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
RARoberto Acosta‐Dighero
Roberto Acosta‐Dighero
Rodrigo Torres-CastroRodrigo Torres-Castro
Rodrigo Torres-Castro
Iván Rodríguez-NúñezIván Rodríguez-Núñez
Iván Rodríguez-Núñez
JRJaviera Rosales‐Fuentes
Javiera Rosales‐Fuentes
JVJordi Vilaró
Jordi Vilaró
BLBernardita Lopetegui
Bernardita Lopetegui

14 March 2022 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
MSMarilina Santero
Marilina Santero
AMAdriana Gabriela Meade
Adriana Gabriela Meade
RARoberto Acosta-Dighero
Roberto Acosta-Dighero
LGLucas González
Lucas González
SMSantiago Melendi
Santiago Melendi
XBXavier Bonfill
Xavier Bonfill

1 September 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
JSJosefina Salazar
Josefina Salazar
JBJavier Bracchiglione
Javier Bracchiglione
KSKarla Salas-Gama
Karla Salas-Gama
AAAlba Antequera
Alba Antequera
AAAriadna Auladell-Rispau
Ariadna Auladell-Rispau
LSLuis C. Saiz
Luis C. Saiz

9 February 2021 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
LCLuis Eduardo Vasconcello - Castillo
Luis Eduardo Vasconcello - Castillo
Rodrigo Torres-CastroRodrigo Torres-Castro
Rodrigo Torres-Castro
NSNicolás Sepúlveda‐Cáceres
Nicolás Sepúlveda‐Cáceres
RARoberto Acosta‐Dighero
Roberto Acosta‐Dighero
SMSebastián Miranda‐Aguilera
Sebastián Miranda‐Aguilera
JVJordi Vilaró
Jordi Vilaró

26 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JBJavier Bracchiglione
Javier Bracchiglione
GRGerardo Rodríguez-Grijalva
Gerardo Rodríguez-Grijalva
CRCarolina Requeijo
Carolina Requeijo
MSMarilina Santero
Marilina Santero
JSJosefina Salazar
Josefina Salazar
XBXavier Bonfill
Xavier Bonfill
Background: The trade-off between systemic oncological treatments (SOTs) and UPSC in patients with primary advanced hepatobiliary cancers (HBCs) is not clear in terms of patient-centred outcomes beyond survival. This overview aims to assess the effectiveness of SOTs (chemotherapy, immunotherapy and targeted/biological therapies) versus UPSC in advanced HBCs. Methods: We searched for systematic reviews (SRs) in PubMed, EMBASE, the Cochrane Library, Epistemonikos and PROSPERO. Two authors assessed eligibility independently and performed data extraction. We estimated the quality of SRs and the overlap of primary studies, performed de novo meta-analyses and assessed the certainty of evidence for each outcome. Results: We included 18 SRs, most of which were of low quality and highly overlapped. For advanced hepatocellular carcinoma, SOTs showed better overall survival (HR = 0.62, 95% CI 0.55–0.77, high certainty for first-line therapy; HR = 0.85, 95% CI 0.79–0.92, moderate certainty for second-line therapy) with higher toxicity (RR = 1.18, 95% CI 0.87–1.60, very low certainty for first-line therapy; RR = 1.58, 95% CI 1.28–1.96, low certainty for second-line therapy). Survival was also better for SOTs in advanced gallbladder cancer. No outcomes beyond survival and toxicity could be meta-analysed. Conclusion: SOTs in advanced HBCs tend to improve survival at the expense of greater toxicity. Future research should inform other patient-important outcomes to guide clinical decision making.